The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Evidence in Practice

Wednesday, 04 January 2017
A new study suggests that a ‘Sit Less’ intervention ‒ breaking sitting with standing and light-intensity walking ‒ may be an alternative to structured exercise to promote blood sugar control in patients with type 2 diabetes, giving improved 24-hour glucose levels and improved insulin sensitivity.
Topics covered:
Wednesday, 04 January 2017
Adding evolocumab to optimised statin therapy results in statistically significant regression of atherosclerosis in patients with coronary artery disease, according to results from the GLAGOV phase 3 trial.
Topics covered:
Wednesday, 04 January 2017
Tackling obesity by offering the opportunity to attend a weight loss programme during a routine consultation is effective, welcomed by patients and takes only 30 seconds, according to a new randomised trial of over 1800 people in the UK.
Topics covered:
Thursday, 27 October 2016
Targeting cardiovascular disease risk factors may be important across a person’s lifetime, as a new study from the US National Institutes of Health shows that efforts to prevent risk factors should extend to those over 65 years of age.
Topics covered:
Thursday, 27 October 2016
Semaglutide, an investigational human glucagon-like peptide-1 (GLP-1) analogue, significantly reduced the risk of the primary composite endpoint of time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke by 26% vs placebo, when added to standard of care in adults with type 2 diabetes at high CV risk.
Topics covered:
Thursday, 27 October 2016
The benefits of statin therapy have been repeatedly underestimated, and the harms exaggerated, due to misinterpretation of the evidence, according to the authors of a major review published in The Lancet recently.
Thursday, 08 September 2016
Intensified and multifaceted treatment of patients with type 2 diabetes and poor prognosis due to microalbuminuria extends median lifetime by 8 years compared with conventional therapy, according to a new long-term Danish follow-up study of the Steno-2 trial.
Topics covered:
Thursday, 08 September 2016
A Scottish study shows that the overall incidence of type 2 diabetes has stabilised over the past 12 years while mortality has declined. The study authors suggest that the increasing prevalence of the disease, from 3.2% in 2004 to 5.1% in 2013 is due to longer survival of patients and not increasing numbers.
Topics covered:

Article search and filter